Clinical trials: Malignancy, open to volunteers
Hepatocellular Carcinoma, Narrow Margin
Adjuvant Stereotactic Body Radiotherapy (SBRT) for Hepatocellular Carcinoma After Hepatectomy With Narrow Margin: a Prospective, Multi-center, Randomized Controlled, Open-labelled, Phase III Study
Hepatocellular carcinoma (HCC) is the sixth prevalent malignancy worldwide. Although surgical excision is considered the standard treatment for resectable HCC, a high rate of postoperative recurrence was observed after partial…
- Conditions
- Hepatocellular Carcinoma, Narrow Margin, Adjuvant Stereotactic Body Radiotherapy, Hepatectomy
- Trial name
- NCT05602974
- Testing
- stereotactic body radiation therapy, regular follow-up
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Cutaneous T-cell Lymphoma (CTCL)
Golidocitinib and Chidamide for Cutaneous T-Cell Lymphoma
This is a prospective, single-center phase I/II study, with the purpose of evaluating the efficiency of golidocitinib combined with chidamide in patients with systemically-treated cutaneous T-cell lymphoma.
- Trial name
- NCT07754890
- Testing
- golidocitinib, Chidamide
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Peking Union Medical College Hospital
Non-small Cell Lung Cancer (NSCLC), Stage IV
Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients
Unfortunately, most patients are already at a very advanced stage when they are diagnosed with lung cancer, i.e. the cancer has already spread outside the lungs forming metastases.
- Trial name
- salVage (NCT06114108)
- Testing
- Systemic therapy alone or in combination with LAT (surgery and/or radiotherapy), Surgery, Radiotherapy
- Where
- 7 sites in Switzerland
- Volunteers
- 128 people
- Sponsor
- Swiss Cancer Institute
Breast Cancer, Stage IV Breast Cancer
Surgery vs. No Surgery for Primary Tumor in De Novo Stage IV Breast Cancer With Solitary Bone Metastases
This is a national multicenter, prospective, randomized controlled trial. The study aims to compare the 5-year overall survival (OS) between patients receiving primary tumor surgery followed by systemic therapy (surgery group)…
- Conditions
- Breast Cancer, Stage IV Breast Cancer, Bone Metastases
- Trial name
- POSITIVE-Bone (NCT07687225)
- Testing
- Primary Tumor Resection, Standard systemic therapy
- Volunteers
- 216 people
- Sponsor
- West China Hospital
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy…
- Conditions
- Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant
- Trial name
- NCT04104776
- Testing
- Tulmimetostat, Enzalutamide
- Where
- 80 sites in United States, France and 5 more
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
NSCLC Stage IV, Brain Metastases
Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis
Non-small cell lung cancer (NSCLC), the most prevalent form of lung cancer, has a significant risk of brain metastasis (BM). Historically, the median overall survival for advanced NSCLC patients with BM was under six months with…
- Trial name
- NCT06501391
- Testing
- PD-L1/PD-1 inhibitor and chemotherapy, SRT or WBRT
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Fudan University
Preoperative, Sleep Disturbance
Preoperative Oral Midazolam to Postoperative Pain Relief in Sleep Disturbance or Anxiety Patients With Colorectal Cancer
Previous studies have indicated a high incidence of sleep disturbances and anxiety symptoms in individuals with colorectal cancers prior to undergoing surgery, leading to worsened postoperative pain, slower recovery, and higher…
- Conditions
- Preoperative, Sleep Disturbance, Anxiety, Midazolam
- Trial name
- POMPPR (NCT06407518)
- Testing
- Midazolam oral solution
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Sarcoma,Soft Tissue, Brachytherapy
Brachytherapy (Iodine-125 Seeds) and Fluzoparib Combination Therapy for Advanced Unresectable Soft Tissue Sarcoma
To evaluate the effectiveness and safety of radioactive particles in combination with the PARP inhibitor fluzoparib in the treatment of advanced inoperable soft tissue sarcoma.
- Conditions
- Sarcoma,Soft Tissue, Brachytherapy, Poly(ADP-ribose) Polymerase Inhibitors
- Trial name
- RAFAS-001 (NCT05894018)
- Testing
- Fluzoparib, Radioactive particle implantation
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Fujun Zhang
Empgliflozin Cardioprotective Effect
Cardioprotective Effect of Empagliflozin in Breast Cancer Patients
Background: Doxorubicin (DOX) remains a cornerstone in adjuvant and neoadjuvant therapy for breast cancer, but its utility is hindered by dose-dependent cardiotoxicity.
- Trial name
- NCT07815808
- Testing
- Empagliflozin (EMPA), Metformin
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- Tanta University
Colorectal Carcinoma
Efficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal Cancer
Efficacy Study of Digoxin Combined with Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal Cancer
- Trial name
- NCT07025850
- Testing
- Digoxin, Fuquinitinib, Tislelizumab
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Fudan University
Cancer of Unknown Primary
Pucotenlimab Combined with MRG002 for HER2-positive Cancer of Unknown Primary
This study is a single-arm, open-label, multicenter Phase II clinical trial designed to observe and evaluate the efficacy and safety of Pucotenlimab in combination with MRG002 in patients with HER2-positive (IHC 2+ or 3+) cancer…
- Trial name
- NCT06869174
- Testing
- Pucotenlimab combined with MRG002
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhiguo Luo, MD, PhD
Hepatocellular Carcinoma
Sialic Acid in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) accounts for approximately 90% of the cases of liver cancer and is associated with high morbidity and mortality.
- Trial name
- NCT06836518
- Testing
- serum sialic acid
- Volunteers
- 100 people
- Sponsor
- Sohag University
Hypopharyngeal Squamous Cell Carcinoma
Neoadjuvant EGFR-ADC Combined With Anti-PD-1 Monoclonal Antibody in Resectable Locally Advanced Hypopharyngeal Squamous Cell Carcinoma
This clinical trial aims to evaluate the efficacy and safety of Becotatug Vedotin (EGFR-ADC) in combination with Pucotenlimab(Anti-PD-1 Monoclonal Antibody) as neoadjuvant therapy for patients with Resectable Locally Advanced…
- Trial name
- RESERVE-HC (NCT07665190)
- Testing
- Becotatug Vedotin and Pucotenlimab
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Gastric Adenocarcinoma
PHASE II EVALUATION OF CYTOREDUCTION SURGERY AND HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (CRS/HIPEC) IN GASTRIC CANCER
This is a Phase II treatment study analyzing the role of preoperative chemotherapy, preoperative laparoscopic HIPEC, and gastrectomy with CRS/HIPEC in gastric adenocarcinoma patients with cytology-positive only carcinomatosis…
- Trial name
- NCT07178808
- Testing
- Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Banner Health
Uterine Cervical Neoplasm, Uterine Cervical Dysplasia
Developing a Combined Molecular Screening and Triage Test for Cervical Cancer in Self-samples
The goal of the COMBISCREEN project is to develop a fully molecular cervical screening and triage approach that is applicable on self-samples, which are an easily accessible and non-invasive source of biomarkers.
- Conditions
- Uterine Cervical Neoplasm, Uterine Cervical Dysplasia, Human Papilloma Virus, HPV-Related Cervical Carcinoma
- Trial name
- COMBISCREEN (NCT06598176)
- Testing
- Colli-Pee 20mL device with UCM, Evalyn Brush
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Universiteit Antwerpen
Neoplasms, Solid Tumor, Breast Neoplasms, Triple-Negative
Intratumoral N17350 in Advanced Solid Tumors
The goal of this clinical trial is to learn if N17350 works to treat advanced solid tumors in adults. It will also learn about the safety of N17350 and help determine the best dose to use in future studies.
- Conditions
- Neoplasms, Solid Tumor, Breast Neoplasms, Triple-Negative, Squamous Cell Carcinoma of Skin, Melanoma
- Trial name
- OP-NEU-101 (NCT07339176)
- Testing
- N17350
- Where
- 9 sites in United States, Australia
- Volunteers
- 275 people
- Sponsor
- Onchilles Pharma Inc
Cutaneous Melanocytic Neoplasm, Large Cutaneous Melanocytic Nevi
Neurocutaneous Melanocytosis Registry
This study will involve collecting information about the regular medical care you receive for large cutaneous melanocytic nevi (LCMN) or neurocutaneous melanocytosis (NCM).
- Conditions
- Cutaneous Melanocytic Neoplasm, Large Cutaneous Melanocytic Nevi, Neurocutaneous Melanocytosis
- Trial name
- NCT04548817
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
COPD, ILD
SWEEP: Shuttle Walking Test for Exercise Evaluation in Pulmonary Resection
This is a prospective observational study that evaluates whether the Shuttle Walking Test (SWT) can predict postoperative symptoms, particularly dyspnea, in patients with chronic respiratory diseases undergoing lung resection.
- Conditions
- COPD, ILD, Bronchiectasis, Lung Cancer NOS
- Trial name
- SWEEP (NCT07102589)
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Seoul National University Bundang Hospital
Plasma Cell Myeloma
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
This is a multi-center, open-label, Phase 2 treatment extension study in participants with multiple myeloma who are still benefitting from isatuximab based therapy following completion of a Phase 1, 2, or 3 parental study.
- Trial name
- NCT05669989
- Testing
- Isatuximab intravenous (IV), Cemiplimab (SAR439684), Dexamethasone
- Where
- 37 sites in United States, Australia and 15 more
- Volunteers
- 70 people
- Sponsor
- Sanofi
Colo-rectal Cancer
Decision Counseling and Follow-up for Shield+ Patients
Prospective, observational, minimal-risk study evaluating decision-making, decisional conflict, intention to undergo complete diagnostic evaluation (CDE), and colonoscopy completion after a positive Shield TM blood-based…
- Trial name
- DCaF (NCT07620535)
- Testing
- Decision Counseling Session
- Where
- United States
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Guardant Health, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.